European Journal of Heart Failure, Journal Year: 2023, Volume and Issue: 25(11), P. 1887 - 1890
Published: Nov. 1, 2023
Language: Английский
European Journal of Heart Failure, Journal Year: 2024, Volume and Issue: 26(6), P. 1419 - 1422
Published: May 13, 2024
Language: Английский
Citations
1
Scientific Reports, Journal Year: 2024, Volume and Issue: 14(1)
Published: June 5, 2024
Abstract Heart failure (HF) poses a significant challenge, often leading to frequent hospitalizations and compromised quality of life. Continuous pulmonary artery pressure (PAP) monitoring offers surrogate for congestion status in ambulatory HF care. This meta-analysis examines the efficacy PAP devices (CardioMEMS Chronicle) preventing adverse outcomes patients, addressing gaps prior randomized controlled trials (RCTs). Five RCTs (2572 participants) were systematically reviewed. significantly reduced HF-related (RR 0.72 [95% CI 0.6–0.87], p = 0.0006) events 0.86 0.75–0.99], 0.03), with no impact on all-cause or cardiovascular mortality. Subgroup analyses highlighted significance CardioMEMS blinded studies. Meta-regression indicated correlation between prolonged follow-up increased reduction hospitalizations. The risk bias was generally high, evidence certainty ranging from low moderate. exhibit promise diminishing events, especially However, their influence mortality remains inconclusive. Further research, considering diverse patient populations intervention strategies extended follow-up, is crucial elucidating optimal role management.
Language: Английский
Citations
1
JACC Heart Failure, Journal Year: 2024, Volume and Issue: 12(11), P. 1845 - 1858
Published: Aug. 14, 2024
Language: Английский
Citations
1
Clinical Research in Cardiology, Journal Year: 2024, Volume and Issue: 113(11), P. 1589 - 1603
Published: Sept. 11, 2024
Language: Английский
Citations
1
Published: Feb. 6, 2024
In this thesis, we first focused on the prognostic impact of mitral regurgitation (MR) across different heart failure (HF) scenarios: chronic worsening HF, acute HF and advanced HF. BIOSTAT-CHF study HELP-HF registry, significant MR was independently associated with worse outcomes among patients respectively. However, in RELAX-AHF-2 trial, moderate-severe had a primary composite endpoint (180-day cardiovascular death or rehospitalization for renal failure) at univariable analyses after adjustment age sex, but not extensive multivariable adjustment. Subsequently, explored pathophysiological mechanisms underlying presence BIOSTAT-CHF, differentially expressed circulating biomarkers without were investigated. A distinct expression profile identified MR, differently versus related to congestion, mineral metabolism, lipid metabolism cachexia, oxidative stress. Finally, determinants changes optimization medical therapy severity dynamically changed up-titration, strong independent impact. Of note, higher ACEi/ARB up-titration left ventricular ejection fraction ≥50% likelihood improvement optimization.
Language: Английский
Citations
0
Journal of Asian Pacific Society of Cardiology, Journal Year: 2024, Volume and Issue: 3
Published: April 9, 2024
This survey study aimed to assess readiness, amongst cardiologists and cardiology trainees, in using a polypill strategy the management of heart failure. A national-level, 21-item was conducted between 1 January 2023 30 June 2023. total 120 participants responded, with clinical practice differing greatly. Potential challenges prescription were mainly surrounding safety cost. Dosing strategies also an important aspect, many believing that polypills should exist various dosing combinations. In addition, evidence focused on tolerability felt important, pre-marketing. demonstrates how implementation may remain challenging, especially Asia-Pacific community.
Language: Английский
Citations
0
European Journal of Preventive Cardiology, Journal Year: 2024, Volume and Issue: 31(11), P. 1361 - 1362
Published: May 7, 2024
Language: Английский
Citations
0
European Journal of Heart Failure, Journal Year: 2024, Volume and Issue: 26(6), P. 1273 - 1277
Published: June 1, 2024
Language: Английский
Citations
0
JACC Heart Failure, Journal Year: 2024, Volume and Issue: unknown
Published: Sept. 1, 2024
Citations
0
Journal of Clinical Medicine, Journal Year: 2024, Volume and Issue: 14(1), P. 139 - 139
Published: Dec. 29, 2024
Background/Objectives: In heart failure (HF) with reduced ejection fraction (HFrEF), the early diagnosis and proper treatment of comorbidities (CMs) are fundamental relevance. Our aim was to assess prevalence CMs among real-world patients requiring hospitalisation for HFrEF investigate effect on implementation guideline-directed medical therapy (GDMT) all-cause mortality (ACM). Methods: The data a consecutive patient cohort hospitalised HF between 2021 2024 were analysed retrospectively. Sixteen (6 CV 10 non-CV) considered. Patients divided into three categories: 0–3 vs. 4–6 ≥7 CMs. GDMT at discharge ACM compared CM categories. predictors 1-year also evaluated. Results: From 388 (male: 76%, age: 61 [50–70] years; NT-proBNP: 5286 [2570–9923] pg/mL; ≥2 cardiovascular–kidney–metabolic disease overlap: 46%), large proportion received (RASi: 91%; βB: 85%; MRA: 95%; SGLT2i: 59%; triple [TT: RASi+βB+MRA]: 82%; quadruple [QT: TT + SGLT2i]: 54%) discharge. Multimorbidity accompanied (p < 0.05) lower application ratio RASi (96% 92% CMs) βB (94% 85% 78%), while MRA (99% 94% 94%) SGTL2i use (61% 59% 57%) did not differ > 0.05). multimorbidity less likely be treated (93% 82% 73%, p = 0.001), no difference detected in QT (56% 54% 50%, 0.685). an increased burden higher (9% 13% 25%, 0.003). risk favourably affected by TT/QT severe left ventricular systolic dysfunction, having ≥5 had unfavourable impact prognosis. Conclusions: According our analysis, can expect favourable outcome. However, modern even applied this population, resulting significantly improved Thus, clinicians should insist early, conscious prognosis-modifying drug regime multimorbid as well.
Language: Английский
Citations
0